Thorac Cardiovasc Surg 2006; 54(3): 162-167
DOI: 10.1055/s-2005-872952
Original Cardiovascular

© Georg Thieme Verlag KG Stuttgart · New York

Tirofiban (Aggrastat®) Protects Platelets and Decreases Platelet-Granulocyte Binding in an Extracorporeal Circulation Model[1]

A. Straub1 , R. Azevedo1 , W. Beierlein1 , H. P. Wendel1 , K. Dietz2 , G. Ziemer1
  • 1Department of Thoracic, Cardiac and Vascular Surgery, University of Tübingen, Tübingen, Germany
  • 2Department of Medical Biometry, University of Tübingen, Tübingen, Germany
Further Information

Publication History

Received February 15, 2005

Publication Date:
26 April 2006 (online)

Preview

Abstract

Objectives: Extracorporeal circulation (ECC) induces platelet activation and inflammation with potentially life-threatening organ dysfunction. Short-acting GP IIb/IIIa inhibitors like tirofiban and eptifibatide protect platelets during ECC without increasing bleeding complications and may reduce inflammation. This study investigates anti-thrombotic and anti-inflammatory effects of different platelet inhibitors. Methods: Control (untreated) and treated (using either 150 ng/mL tirofiban, 2.5 µg/mL eptifibatide, 0.7 µg/mL milrinone, 15 µg/mL dipyridamol, or 300 KIU/mL aprotinin) heparinized blood of healthy volunteers (n = 6) was recirculated in a well-established ECC model (Chandler loop). Percentage of platelet aggregates, P-selectin-expressing (activated) platelets, CD15-positive aggregates (indicating proinflammatory platelet-granulocyte binding), and platelet counts were determined before (baseline) and after 30 minutes recirculation in unstimulated and ADP-stimulated samples using flow cytometry. Statistical analysis was performed using multifactor ANOVA after transforming the data (logarithms for counts and log odds for percentages). Least square means were backtransformed to obtain appropriate means and their 95 % confidence intervals. Multiple post-hoc comparisons were performed by Tukey's HSD test with a global alpha of 5 %. Results: Significant inhibition was observed for: 1) ECC-induced platelet aggregation by tirofiban (unstimulated: 2.2-fold/stimulated: 2.46-fold), eptifibatide (unstimulated: 1.96-fold/stimulated: 2.65-fold), and milrinone (unstimulated: 1.87-fold/stimulated: 1.37-fold); 2) ECC-induced P-selectin expression by tirofiban (unstimulated: 3.95-fold/stimulated: 2.54-fold), and eptifibatide (unstimulated: 5.87-fold/stimulated: 3.28-fold); 3) ECC-induced platelet loss by tirofiban (1.27-fold), and eptifibatide (1.25-fold); 4) ECC-induced platelet-granulocyte binding by tirofiban (unstimulated: 2.25-fold/stimulated: 1.59-fold), but not by eptifibatide. Conclusions: Amongst the investigated drugs only GP IIb/IIIa inhibitors decreased activation, aggregation, and loss of platelets during ECC but acted differently on platelet-granulocyte interaction. A short-acting GP IIb/IIIa inhibitor with the potential to inhibit platelet activation and platelet-leukocyte interaction should be considered both for platelet protection and inhibition of platelet-mediated inflammation during ECC.

1 This work has been presented at the 34th Annual Meeting of the German Society for Thoracic and Cardiavascular Surgery (Hamburg, February 15, 2005, session no. 49). The work was supported by a grant of the Medical Faculty of the University of Tübingen (fortüne-program; project-no.: 1164-0-0).

References

1 This work has been presented at the 34th Annual Meeting of the German Society for Thoracic and Cardiavascular Surgery (Hamburg, February 15, 2005, session no. 49). The work was supported by a grant of the Medical Faculty of the University of Tübingen (fortüne-program; project-no.: 1164-0-0).

Dr. A. Straub

Department of Thoracic, Cardiac, and Vascular Surgery
Tübingen University Hospital

Hoppe-Seyler-Straße 3

72076 Tübingen

Germany

Phone: + 4970712986638

Fax: + 49 70 71 29 40 47

Email: anstraub@nexgo.de